Estrogen withdrawal — the rapid drop in estrogen during the late luteal phase of the menstrual cycle — is the leading mechanism explaining why roughly half of women with migraine see attacks cluster around their period. The drop, not the absolute level, is the trigger event.

This page covers the mechanism, the clinical implications, and why stable-estrogen regimens sometimes help.

The hormonal pattern

In a typical 28-day cycle:

  • Day 1: menstruation begins, estrogen at its low point.
  • Days 5–13: estrogen rises in the follicular phase.
  • Day 14: peak around ovulation.
  • Days 15–24: high in mid-luteal, secondary peak around day 21.
  • Days 25–28: rapid drop as the corpus luteum involutes.
  • Day 1 next cycle: low again.

The high-risk window for menstrual migraine — days -2 through +3 of menstruation — exactly tracks the estrogen withdrawal phase (days 26–28 + days 1–3 of the next cycle).

The mechanism is the drop, not the level

The key insight from research is that migraine doesn’t respond to absolute estrogen level, it responds to change. This explains:

  • Pregnancy improvement — high stable estrogen during pregnancy reduces attack frequency for most women.
  • Postpartum spike — abrupt postpartum drop triggers attacks in ~30 percent of women within days.
  • Postmenopause stability — established postmenopause (after the transition completes) often sees fewer attacks at the low-but-stable estrogen state.
  • Continuous monophasic contraceptives — flattening the cyclical drop reduces attack frequency in many women.
  • Perimenopausal worsening — unpredictable hormonal fluctuations worsen migraine even though average estrogen is similar to earlier reproductive years.

The mechanism likely involves estrogen’s modulation of multiple migraine-relevant systems — cortical excitability, CGRP release, serotonergic tone, trigeminovascular sensitivity. Rapid change disturbs the equilibrium of all of these simultaneously.

Clinical implications

Diagnosis

Pure menstrual migraine (attacks exclusively in the day -2 to +3 window) and menstrually-related migraine (attacks in that window plus other times) are formal ICHD-3 entities. Tracking cycle position for several months can identify the pattern even when the patient hasn’t explicitly noticed it.

Treatment options that target the drop

  • Continuous monophasic combined contraceptives — eliminate the cyclical drop entirely. Effective for many women but contraindicated in migraine with aura due to stroke risk.
  • Estrogen supplementation around the drop — patches or gels applied in the perimenstrual window can blunt the withdrawal. Requires gynecologist guidance.
  • Mini-prophylaxis with triptans — short courses of long-acting triptans (frovatriptan, naratriptan) taken for 5–6 days perimenstrually reduce attack frequency.

These are all real medical interventions that need clinical supervision. Hermly will not recommend any of them — these are conversations with a gynaecologist or headache specialist with experience in hormonal headache.

What Hermly tracks

When Apple Health cycle data is available and cycle tracking is enabled in Hermly Settings:

  • Cycle day — the day-1-indexed position in the current cycle.
  • Cycle phase — menstrual / follicular / ovulatory / luteal, derived from cycle day.
  • High-risk window flag — true on perimenstrual days (25–28
    • 1–2) and ovulatory days (13–16).

These three features feed the cohort prediction model. For women with hormonal migraine pattern, cycle position is often one of the strongest single predictors when available.

What this isn’t

Not a treatment plan for menstrual migraine. Not a contraceptive recommendation. The hormonal management of migraine is specialist territory — a gynaecologist working with a headache specialist is the right pairing for the complex cases.